Financial Performance - The company reported a gross profit of approximately HKD 34,324,000 for the fiscal year 2023, a decrease of about HKD 1,066,633,000 compared to HKD 1,100,957,000 in fiscal year 2022, resulting in a gross margin of 16.19%, down 43.27 percentage points from 59.46% in the previous year[28]. - The net loss attributable to the company's owners for fiscal year 2023 was approximately HKD 95,447,000, compared to a net profit of HKD 258,087,000 in fiscal year 2022, primarily due to a decline in demand for COVID-19 testing services and rapid antigen test kits following the easing of quarantine regulations[32]. - The company reported total revenue for the year ended December 31, 2023, was HKD 211,985,000, a decrease of 88.6% from HKD 1,851,601,000 in 2022[115]. - The net loss for the year was HKD 140,706,000, compared to a profit of HKD 705,568,000 in 2022, indicating a substantial downturn in financial performance[115]. - The total comprehensive loss for the year was HKD 174,253,000, compared to a comprehensive income of HKD 654,250,000 in 2022[117]. - The company reported a basic and diluted loss per share of HKD 9.9 for the year, down from earnings of HKD 26.8 per share in the previous year[117]. - The company reported external customer revenue of HKD 211,985,000 for the year ending December 31, 2023, with contributions from various segments including medical and healthcare services (HKD 192,910,000) and pharmaceutical products (HKD 881,000)[138]. - The total loss before tax for the year was HKD 142,025,000, with a net loss of HKD 140,706,000 after tax[138]. - The group reported a loss of HKD 95,447,000 for the year 2023, compared to a profit of HKD 258,087,000 in 2022[197]. Revenue and Demand Trends - The company experienced a significant decrease in revenue from medical laboratory testing and health check services, which contributed to the overall lower demand in fiscal year 2023[22]. - The demand for COVID-19 related laboratory testing services significantly decreased due to the relaxation and subsequent cancellation of quarantine regulations[186]. - The revenue of the division decreased from approximately HKD 1,619,568,000 in 2022 to approximately HKD 192,910,000 in 2023, representing a decline of 88.09%[186]. - The total revenue for Hong Kong in 2023 was HKD 211,972,000, down from HKD 1,851,331,000 in 2022, indicating a significant decrease[191]. Assets and Liabilities - The company reported total assets of HKD 662,362,000 for the year ended December 31, 2023, down from HKD 1,470,491,000 in 2022[104]. - The total liabilities decreased from HKD 643,971,000 in 2022 to HKD 171,636,000 in 2023, a reduction of approximately 73%[105]. - The company’s total current assets decreased to HKD 261,166,000 in 2023 from HKD 884,757,000 in 2022[104]. - The company’s non-current assets included property, plant, and equipment valued at HKD 100,535,000, an increase from HKD 96,073,000 in 2022[104]. - The company’s goodwill decreased to HKD 107,181,000 in 2023 from HKD 110,083,000 in 2022[104]. - The company’s trade receivables and other receivables decreased significantly to HKD 39,636,000 in 2023 from HKD 765,547,000 in 2022[104]. Operational Changes and Strategies - The company plans to expand its routine medical laboratory testing and health check services to provide high-throughput public health screening services in Hong Kong, responding to the reduced demand for COVID-19 testing[39]. - The company has established a high-standard molecular biology laboratory in Hong Kong, providing next-generation sequencing (NGS) cancer companion diagnostic tests since July 2022, and is seeking collaborations with local hospitals and clinical laboratories[40]. - The company aims to become the first service provider in Greater China to offer boron neutron capture therapy for difficult-to-treat head and neck cancer patients, with plans to enhance advanced tumor radiation therapy services in mainland China, Hong Kong, and Macau[41]. - The company continues to evaluate its strategic options for future growth and market expansion[145]. Investments and Commitments - The company has committed to building and operating a cancer treatment center using a boron neutron capture therapy system in Hainan, with the system being supplied by Sumitomo Heavy Industries, Ltd.[53]. - The company injected a total of RMB 48,000,000 into Shanghai Longyao Biotechnology Co., Ltd. as part of its investment strategy[49]. - The company has authorized but not contracted capital commitments totaling HKD 208,295,000 for the fiscal year 2023, compared to HKD 237,541,000 in 2022[75]. - The company has made an initial payment of approximately HKD 51,765,000 for the purchase of boron neutron capture therapy equipment, with a total contract price of approximately HKD 176,820,000[77]. Employee and Operational Costs - The total employee cost for the fiscal year 2023 was approximately HK166,735,000 in the previous year, with a total of 162 full-time employees as of December 31, 2023[60]. - The company’s operating expenses and financing costs were impacted by the overall decline in business activity due to the pandemic[30]. - The total contributions made by the company to the retirement plans for the fiscal year 2023 amounted to approximately HKD 2,996,000, a decrease from HKD 3,271,000 in the fiscal year 2022[61]. Governance and Compliance - The company has complied with the corporate governance code as per GEM listing rules, ensuring high standards of corporate governance and transparency[64]. - The company has maintained the public float as required by GEM listing rules[73]. - The company has conducted five audit committee meetings during the fiscal year 2023 to review financial performance and compliance procedures[71]. Future Outlook - Future outlook remains uncertain due to the substantial decrease in both total equity and non-controlling interests, which may impact investor confidence[106]. - The company is exploring market expansion opportunities, although specific strategies were not disclosed in the financial report[108].
中国生物科技服务(08037) - 2023 - 年度业绩